Skip to main content
SpringerLink
Log in

Saruplase in myocardial infarction

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Saruplase is an unglucosylated single-chain recombinant urokinase-type plasminogen activator. Dose finding studies in patients with acute myocardial infarction indicated that a dose of 80 mg of saruplase, given as a bolus of 20 mg and iv infusion of 60 mg in one hour, led to excellent patency figures.

Saruplase is most effective when combined with a bolus of 5000 IU heparin followed by an iv heparin infusion for at least 24 hours.

When saruplase is compared to other thrombolytic agents (streptokinase, alteplase, urokinase), it becomes apparent that its profile is excellent. Early patency rates are at least comparable to alteplase. Further reocclusion rates of saruplase after one day are lower than those of streptokinase and alteplase. Patency rates 24–72 hours after start of medication are comparable between saruplase and urokinase.

The large database in over 6000 patients shows that saruplase, in comparison to the other thrombolytic agents, is safe. Its bleeding complication rate is significantly lower than streptokinase, and a trend to lower in-hospital mortality is observed when compared to urokinase.

Summarizing, when comparing to the presently available thrombolytic agents, saruplase is a fast acting, effective and safe thrombolytic agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bär PW, Vermeer F, de Zwaan C, Ramentol M, Braat S, Simoons ML. Value of admission electrocardiogram in predicting outcome of thrombolytic therapy in acute myocardial infarction.Am J Cardiol 1987;59:6–13.

    PubMed  Google Scholar 

  2. Gruppo Italiano per lo Studio della Streptochinase nell' Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Lancet 1986;1:397–402.

    Google Scholar 

  3. Vermeer F, Simoons M, Bär FW, Tyssen JGP, Domburg v. RT, Serruys PW. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase.Circulation 1986;74:1379–1389.

    PubMed  Google Scholar 

  4. Mathey DG, Schofer J, Sheehan PH, Becher H, Tilsen V, Dodge HT. Intravenous urokinase in acute myocardial infarction.Am J Cardiol 1985;55:878–882.

    PubMed  Google Scholar 

  5. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial.N Engl J Med 1985;312:932–936.

    Google Scholar 

  6. Van de Werf F, Arnold AER. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.Br Med J 1988;297:1374–1379.

    Google Scholar 

  7. Chesebro JH, Knatterud G, Roberts R, Borer Y, Cohen AS, Dalen J. Thrombolysis in myocardial infarction (TIMI) trial, phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase.Circulation 1987;76:142–154.

    PubMed  Google Scholar 

  8. Verstraete M, Bernard R, Bory M, Brown RW, Collen D, de Bono DP. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.Lancet 1985;1:842–847.

    PubMed  Google Scholar 

  9. Simoons ML, Arnold AER, Betriu A, de Bono DP, Col J, Dougherty FC. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty.Lancet 1988;2:197–203.

    PubMed  Google Scholar 

  10. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction.Circulation 1990;82:781–791.

    PubMed  Google Scholar 

  11. ISIS 2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.Lancet 1988;2:349–360.

    Google Scholar 

  12. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction.N Engl J Med 1993;329:1615–1623.

    Google Scholar 

  13. Relik-van Wely L, Visser RF, Van der Pol J, Bartholomue I, Couvee JF, Drowst H. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: Results of the anistreplase reocclusion multicentre study (ARMS).Am J Cardiol 1991;68:296–300.

    PubMed  Google Scholar 

  14. Bonnier HJRM, Visser RF, Klomps HC, Hoffman MJ, El Deeb MF, El Gamal MIM. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.Am J Cardiol 1988;62:25–30.

    PubMed  Google Scholar 

  15. Marder VJ, Rothbarth RL, Fitzpatrick PG, Francis CW. Rapid lysis of coronary artery thrombi with anisoylated plasminogen streptokinase activator complex: Treatment by bolus intravenous injection.Ann Intern Med 1986;104:304–310.

    PubMed  Google Scholar 

  16. Hanbücken FW, Schneider J, Günzler WA, Friderichs E, Giertz H, Flohe L. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.Arzneim Forsch Drug Res 1989;37:993–997.

    Google Scholar 

  17. Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR. Recombinant single-chain urokinase plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.Thromb Res 1988;51:63–74.

    PubMed  Google Scholar 

  18. Van de Werf F, Jang IK, Collen D. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): Dose-response in dogs with coronary artery thrombosis.J Cardiovasc Pharmacol 1987;9:91–93.

    PubMed  Google Scholar 

  19. Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Günzler WA. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinse in baboons: Effect on regional blood flow, infarct size and hemostatis.J Am Coll Cardiol 1986;8:118–124.

    PubMed  Google Scholar 

  20. Van der Werf F, Vanhaecke J, De Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single chain urokinase-type plasminogen activator in patients with acute myocardial infarction.Circulation 1986;74:1066–1070.

    PubMed  Google Scholar 

  21. Diefenbach C, Erbel R, Pop T, Mathey D, Schofer Y, Hamm C. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.Am J Cardiol 1988;61:966–970.

    PubMed  Google Scholar 

  22. Tebbe U, Windeier J, Boesl J, Hoffman H, Wojcik J, Ashmawy M. Thrombolysis with recombinant unglucosylated Single-Chain Urokinase-Type Plasminogen activator (Saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (AIMITS Study)J Am Coll Cardiol 1995;26:365–373.

    PubMed  Google Scholar 

  23. Bär FW, Meyer J, Michels R, Uebis R, Gange S, Barth H. The effect of taprostene in patients with acute myocardial infarction treated with thrombolytics: Results of the START study.Eur Heart J 1993;14:1118–1126.

    PubMed  Google Scholar 

  24. Schneider J. Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model.Arzneim Forsch Drug Res 1990;40(II):1180–1184.

    Google Scholar 

  25. Schneider J. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.Thromb Res 1991;64:677–689.

    PubMed  Google Scholar 

  26. Barth H, Lintz W, Michel G, Osterloh G, Scipp U, Flohe-L. Inhibition of platelet aggregation by intravenous administration of the biochemically stable prostacyclin analogue CG4203 in man.Naunyn Schmiedebergs Arch Pharmacol1983;(Suppl 324).

  27. Groves R, Schneider J, Flohé L. Cooperative action of the prostacyclin analogue taprostene and the fibrinolytic prourokinase (r-scu-PA) in experimental artery thrombosis. In: Schrör K, Sinzinler M, eds.Prostaglandins in Clinical Research: New York: Alan R. Liss 1989:603–607.

    Google Scholar 

  28. Flohé L, Böhlke H, Frankus E, Kim SMA, Gintz W, Goschen G. Designing prostacyclin analogues.Drug Res 1983;33:1240.

    Google Scholar 

  29. Kaliman J, Fitscha P, Barth H, Sinzinger H. Clinical and platelet effects of CG 4203, a stable PGI2 analogue. In: Schör K, Sinzinger M, eds.Abstracts of the 6th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 3–6, New York: Alan R. Liss, 1986, p 443.

    Google Scholar 

  30. PRIMI Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction.Lancet 1989;1:863–886.

    Google Scholar 

  31. Hoffmann JJML, Vijgen M, Nieuwenhuizen A. Comparison of the specificity of four fibrinogen assays during thrombolytic therapy.Fibrinolysis 1990;4:121–123.

    Google Scholar 

  32. Michels R, Hoffmann H, Windier J, Barth H, Hopkins G. A double-blind multicentre comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction. Report of the SUTAMI study group.J Thrombosis and Thrombolysis 1995;2:117–124.

    Google Scholar 

  33. The Belgian Saruplase Alteplase Trial Group. Effects of alteplase and saruplase on hemostatic variables: A singleblind, randomized trial in patients with acute myocardial infarction.Cor AH Dis 1991;2:349–355.

    Google Scholar 

  34. The SESAM Investigators. Early patency and reocclusion in acute myocardial infarction. A comparison between the thrombolytic agents saruplase and alteplase. Results of the SESAM trial.J Am Coll Cardiol 1994;Feb:345 (abstract).

    Google Scholar 

  35. Vermeer F, Bär FW, Windeler J, Schenkel W. Saruplase, a new fibrin specific thrombolytic agent. Final results of the PASS study (1698 patients) (abstract).Circulation 1993;88:292.

    Google Scholar 

  36. Hatzler GO, Rutherford BD, McConahay DR, Johnson WL, McCallister BD, Gura GM. Percutaneous transluminal coronary angiography with and without thrombolytic therapy for treatment of acute myocardial infarction.Am Heart J 1983;106:965–973.

    PubMed  Google Scholar 

  37. Simoons ML, Serruys PW, Serruys VD Brand M, Fioretti L. Thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival.J Am Coll Cardiol 1986;7:717–728.

    PubMed  Google Scholar 

  38. Hogg KJ, Gemmill JD, Burns JM, Gibson WK, Rae AP, Dunn G. Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction.Lancet 1990;335:254–258.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University Hospital Maastricht, P.O. Box 5800, 6202, AZ Maastricht, the Netherlands

    Frits W. Bär M.D. & Frank Vermeer

  2. Department of Cardiology, Catherina Hospital Eindhoven, Eindhoven, the Netherlands

    Rolf Michels

  3. Department of Cardiology, CHR Citadelle Liège, Liège, Belgium

    Jean Boland

  4. Department of Cardiology, Universitätsklinik Johannes Gutenberg, Mainz, Germany

    Jurgen Meyer

  5. Grünenthal GmbH, Aachen, Germany

    Gwyn Hopkins, Hannes Barth & Wolfgang A. Grünzier

Authors
  1. Frits W. Bär M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Vermeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rolf Michels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Boland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jurgen Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gwyn Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hannes Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfgang A. Grünzier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bär, F.W., Vermeer, F., Michels, R. et al. Saruplase in myocardial infarction. J Thromb Thrombol 2, 195–204 (1995). https://doi.org/10.1007/BF01062710

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01062710

Key words

Search

Navigation